Lexeo Therapeutics, Inc. Common Stock(LXEO)Earnings, Financials & Key RatiosLexeo Therapeutics, Inc. Common Stock (LXEO) stock price & volume — 10-year historical chart
Investment Thesis • Updated 2026Q1
the company's cash reserves have declined from $195.1 million in 2024Q1 to $63 million in 2025Q4, suggesting that imminent liquidity constraints will likely force dilutive equity financing in the near term.
Lexeo Therapeutics, Inc. Common Stock (LXEO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Lexeo Therapeutics, Inc. Common Stock (LXEO) EPS & revenue vs analyst estimates — last 4 quarters
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 11, 2026 | $0.25vs $0.29+13.8% | — |
| Q2 2026 | Mar 30, 2026 | $0.27vs $0.32+15.6% | — |
| Q4 2025 | Nov 5, 2025 | $0.33vs $0.48+31.3% | — |
| Q3 2025 | Aug 14, 2025 | $0.60vs $0.64+6.3% | — |
Recent stock market news and headlines for Lexeo Therapeutics, Inc. Common Stock (LXEO)
Lexeo Therapeutics, Inc. (LXEO) Discusses Phase III Program Design and Durable Cardiac Improvements in Friedreich's Ataxia Transcript
Lexeo Therapeutics is a clinical-stage gene therapy company focused on inherited cardiac diseases. Their main value driver is LX2006 for Friedreich's ataxia (FA) cardiomyopathy. LX2006 currently has a clearer SUNRISE-FA 2 pivotal path, and we should get its topline data by 2H2027.
Published findings in JAMA Cardiology demonstrate LX2006 generally well tolerated, with early signs of efficacy in Phase I/II studies
Lexeo Therapeutics, Inc. (LXEO) Shareholder/Analyst Call Transcript
Lexeo Therapeutics Inc. (NASDAQ:LXEO) stock rose Monday as the company announced a regulatory update regarding its pivotal SUNRISE-FA 2 trial for gene therapy candidate LX2006.
Key metrics vs top competitors for Lexeo Therapeutics, Inc. Common Stock (LXEO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.60 | $361.2M | -2.47 | — | — | -55% | — | |
| $3.99 | $435.68M | -1.99 | — | — | -70.79% | — | |
| $374.68 | $11.05B | 54.78 | 33.94% | 53.92% | 19.25% | — | |
| $0.07 | $30.66M | -0.17 | -31.57% | -356.89% | — | — | |
| $33.70 | $3.31B | -5.78 | 20.13% | -91.03% | — | — | |
| $14.49 | $4.55B | -164.85 | 20.05% | -4.27% | -12.02% | — |
Lexeo Therapeutics, Inc. Common Stock (LXEO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Lexeo Therapeutics, Inc. Common Stock (LXEO) SEC filings — annual & quarterly reports (10-K, 10-Q)
May 11, 2026·SEC
Apr 30, 2026·SEC
Mar 30, 2026·SEC
Get notified when LXEO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Lexeo Therapeutics, Inc. Common Stock (LXEO) stock FAQ — growth, dividends, profitability & financials explained
Lexeo Therapeutics, Inc. Common Stock (LXEO) reported a net loss of $87.5M for fiscal year 2025.
Lexeo Therapeutics, Inc. Common Stock (LXEO) has a return on equity (ROE) of -55.0%. Negative ROE indicates the company is unprofitable.
Lexeo Therapeutics, Inc. Common Stock (LXEO) had negative free cash flow of $98.4M in fiscal year 2025, likely due to heavy capital investments.
